Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- View the Talks
-
1. Mononuclear phagocytes - origins, fates and functions
- Prof. Steffen Jung
-
2. Transcription factors in macrophage differentiation
- Dr. Michael Sieweke
-
3. Fetal macrophages
- Prof. Paul Martin
-
4. The alveolar macrophage
- Dr. Ronald G. Crystal
-
5. Airway macrophages in health and disease
- Prof. Tracy Hussell
-
6. Intestinal macrophages - heterogeneity, origins and functions
- Prof. Allan Mowat
-
7. Osteoclasts: what do they do and how do they do it?
- Prof. Steven L. Teitelbaum
-
8. The biology of Fc receptors and complement receptors
- Prof. Steven Greenberg
-
10. Tumour-associated macrophages
- Prof. Michele De Palma
- Dr. Mario Squadrito
-
11. The recognition of pathogens by C-type lectins
- Prof. Gordon D. Brown
-
12. Macrophage phagocytosis
- Prof. Joel Swanson
-
13. Macrophage CD36 and atherosclerosis
- Dr. Maria Febbraio
-
14. Toll-Like receptor signaling and the innate immune response
- Dr. Kate Fitzgerald
-
15. Innate immune receptors as mediators of systemic inflammation and pathogenesis of malaria
- Prof. Ricardo Gazzinelli
-
17. Triggering receptors expressed on myeloid cells (TREM)
- Dr. Daniel W. McVicar
-
18. Influence of eicosanoid lipid mediators on macrophage innate immune functions
- Prof. Marc Peters-Golden
-
19. Macrophage paired receptor interactions
- Prof. Neil Barclay
-
20. Macrophage heterogeneity in atherosclerosis regression
- Prof. Edward Fisher
-
21. Gaucher disease: from lysosomal storage to immunopathology
- Prof. Johannes M.F.G. Aerts
-
22. Macrophage in asthma
- Prof. Douglas Robinson
-
23. The macrophage mannose receptor
- Dr. Luisa Martinez-Pomares
-
24. Myeloid-derived suppressor cells in cancer
- Prof. Dmitry Gabrilovich
-
25. EGF-TM7 receptors
- Dr. Jörg Hamann
- Dr. Hsi-Hsien Lin
-
26. Macrophages in helminth infection
- Prof. Judith Allen
- Archived Lectures *These may not cover the latest advances in the field
-
27. Immunosuppressive mechanisms in myeloid cells
- Prof. Dmitry Gabrilovich
Printable Handouts
Navigable Slide Index
- Introduction
- Human tumors are infiltrated by leukocytes
- TAMs in different tumor microenvironments
- TAM infiltration in Hodgkin's lymphoma patients
- TAM infiltration and poor prognosis
- TAMs promote tumor progression
- TAM ablation decreases tumor progression
- TAMs provide extrinsic support to tumor growth
- Inflammation and cancer: role of TAMs
- Chronic inflammation promotes tumor initiation
- Chronic inflammation increases cancer risk
- NSAIDs as cancer preventive agents
- Inflammation and cancer: role of NF-kB
- The multifaceted role of NF-kB
- Targeting NF-kB activation in myeloid cells
- TAMs: matrix remodeling, invasion & intravasation
- TAMs: ECM-remodeling & EMT-promoting factors
- TAMs localize closely to blood vessels
- TAMs facilitate tumor cell intravasation
- A paracrine loop between TAMs and tumor cells
- Tumor cell extravasation and metastasis
- T-cells stimulate pro-metastatic activity of TAMs
- TAMs promote angiogenesis
- TAM elimination blocks tumor angiogenesis
- TAM deficiency reduces tumor angiogenesis
- TAMs comprise distinct subsets
- TEMs are a distinct TAM subset
- TEMs are mostly perivascular in tumors
- TEMs are required for tumor angiogenesis
- MRC1+ TAMs overlap with TEMs in tumors
- MRC1+ and CD11c+ are the vast majority of TAMs
- Tumors contain distinct MRC1+/CD11c+ ratios
- TAM heterogeneity in tumors: 3 distinct subsets
- TIE2+ TAMs overlap with MHC II low TAMs
- TAM heterogeneity: toward marker definition
- Origins of TAMs: M1-M2 polarization
- Origins of TAMs: committed precursors
- TAM precursors: hypotheses and findings
- Tumor responses to cancer therapies: TAMs' role
- Reprogramming TAMs to inhibit tumor growth
- Reprogramming TAMs to inhibit tumor progression
- HRG skews TAMs from MRC1+ to CD11c+
- Skewing associates with vascular normalization
- TAMs and cancer therapies
- Future directions
- Leukocyte signatures in breast cancer patients
- Credits and acknowledgements
Topics Covered
- The correlation between Tumor Associated Macrophage (TAM) infiltration and tumor progression in cancer patients
- Evidence for a protumoral function of TAMs in mouse tumor models
- Hallmark features of TAMs enable tumor progression
- Promotion of inflammation
- Chronic inflammatory diseases and cancer risk
- Promotion of matrix remodeling
- Promotion of tumor cell invasion
- Promotion of metastasis
- Promotion of angiogenesis
- TAM heterogeneity in tumors
- Identification and characterization of TAM subsets in mouse tumor models
- TIE2-expressing macrophages and inflammatory TAMs
- Origins of TAM subsets: Distinct hypothesis
- Tumor responses to anticancer therapies: Role of TAMs
- Reprogramming TAMs from a pro- to an anti-tumoral function
- Deciphering TAM heterogeneity in human cancer
- Complexity of leukocyte infiltrates in human cancer
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
De Palma, M. and Squadrito, M. (2012, May 8). Tumour-associated macrophages [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/YEEE9744.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Michele De Palma has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
- Dr. Mario Squadrito has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Immunology & Inflammation
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is Michele De Palma,
and I'm group leader at the Angiogenesis and Tumor Targeting
Unit of the San Raffaele Scientific Institute in Milan.
I've been appointed recently as the assistant professor at the ISRED Institute in Lausanne.
Mario Leonardo Squadrito, a PhD student in my lab,
has contributed to the writing of this talk on tumor-associated macrophages.
0:21
Tumors are like complex organs that arise from normal tissues.
They are not only made of transformed malignant cells,
but also contain a vast assortment of non-transformed cells,
which make up the so called, tumor stroma.
The tumor stroma comprises of blood vessels,
which provide oxygen and nutrients to the growing tumor mass,
fibroblasts, which together with the tumor cells,
produce several components of the extracellular matrix,
and a variety of infiltrating cells of hematopoietic origin, also known as leukocytes.
As shown in panels A,
the normal non-transformed breast and prostate tissues contain sparse leukocytes.
The majority of these cells represent tissue raised in macrophages.
As shown in panels B,
the malignant breast and prostate are heavily infiltrated by leukocytes,
clearly outnumbering those present in the normal breast and prostate tissue.
Of these tumor-associated leukocytes,
a substantial fraction is represented by tumor-associated macrophages.
1:24
Tumor-associated macrophages are present in distinct tumor microenvironments.
For example, they are often very abundant in
the stromal areas made of connective tissue that surround the tumor nodules.
Macrophages are also found in close proximity to blood vessels,
both in stromal and tumor cell areas.
Another tumor microenvironment where macrophages generally
accumulate are the peri-necrotic or hypoxic tumor areas.
Low oxygen tension, also known as hypoxia,
stimulates the tumor cells to express several monocyte macrophage chemoattractants.
This promotes monocyte recruitment and macrophage accumulation
in both mouse and human tumors.
Once recruited, macrophages are retained in hypoxic tumor areas
due to abrogation of chemotactic signal transduction,
and downregulation of chemoattractant receptors.
Hypoxia then enhances the expression of
several proangiogenic and protumoural factors in the macrophages,
by activating hypoxia-inducible factors.